FEMY 8-K
Femasys Inc (FEMY)
8-K
2025-08-08
For: 2025-08-08
View Original
Added on
April 06, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 8, 2025
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(770 ) 500-3910
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instructions A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each
exchange
on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|
Item 2.02
|
Results of Operations and Financial Condition. Other Events
|
On August 8, 2025, Femasys Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025 and provided a corporate update. A copy of the press
release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such
filing.
| Item 9.01 |
Financial Statements and Exhibits.
|
| (d) |
Exhibits.
|
|
Exhibit
No.
|
Description
|
|
Press Release of Femasys Inc. dated August 8, 2025
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL Document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Femasys Inc.
|
||
|
By:
|
/s/ Kathy Lee-Sepsick
|
|
|
Names: Kathy Lee-Sepsick
|
||
|
Title: Chief Executive Officer
|
||
|
Date: August 8, 2025
|
||
Exhibit 99.1
Femasys Announces Second Quarter Financial Results for 2025
-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio --
ATLANTA, August 8, 2025 -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the
second quarter of 2025.
Corporate Highlights from 2Q 2025 to date
| • |
Announced European Union Medical Device Regulation approval of FemBloc®, the first global regulatory endorsement of our groundbreaking non-surgical permanent birth
control solution
|
| • |
Secured first European order for FemBloc from Spain distribution partners for approximately $400,000
|
| • |
Announced Australian and New Zealand regulatory approvals for FemaSeed® and FemVue®, a cost-effective first step in fertility
|
| • |
Announced new Chief Commercial Officer to help drive execution and global growth
|
| • |
Announced partnership with Carolinas Fertility Institute, one of America’s best fertility clinics, to offer FemaSeed in its eight locations
|
| • |
Announced pricing of underwritten public offering and concurrent private placement with gross proceeds of $4.5 million
|
“Our second quarter marked several significant milestones for Femasys as we continue to secure key regulatory approvals, add partners, and strengthen our team to accelerate
the commercialization of our innovative fertility portfolio across the globe,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. “European approval of the entire FemBloc System announced in June marks the first global regulatory
endorsement of our groundbreaking non-surgical permanent birth control solution. FemBloc is commercially available through strategic distribution partnerships in select countries in Europe beginning in Spain, who placed their initial order, and we
will seek additional country approvals while continuing to enroll participants in our FDA IDE-approved late-stage pivotal trial for U.S. approval.
“Regulatory approvals for FemaSeed in Australia and New Zealand announced in July also provide us with the opportunity to pursue meaningful commercial opportunities as we
continue to grow revenue and broaden our global footprint. Our new partnership with Carolinas Fertility Institute will help us reach and support more patients earlier in their fertility journey. We look forward to building upon this momentum as we
work towards transforming the fertility sector not only for patients, but also providers.”
Financial Results for Quarter Ended June 30, 2025
| • |
Sales increased by $187,784, or 84.8%, to $409,268 for the three months of 2025, compared to $221,484 for the three months of 2024 due to sales of FemaSeed and FemVue.
|
| • |
Research and development expenses decreased by $561,446, or 28.4%, to $1,414,429 for the three months of 2025 compared to $1,975,875 for the three months of 2024 primarily due to
commercialization of development products into inventory and reduced clinical costs, partially offset by increased compensation costs.
|
| • |
Net loss was $4,585,922, or ($0.16) per basic and diluted share attributable to common stockholders, for the three-month period ended June 30, 2025, compared to a net loss of $4,684,574, or ($0.21)
per basic and diluted share attributable to common stockholders, for the three-month period ended June 30, 2024.
|
| • |
Cash and cash equivalents as of June 30, 2025, was approximately $3.2 million and the Company had an accumulated deficit of approximately $137.7 million. The Company expects, based on its current operating plan, our
current cash and cash equivalents will be sufficient to fund its ongoing operations into early fourth quarter of 2025.
|
Financial Results for Six Months Ended June 30, 2025
| • |
Sales increased by $257,908, or 52.4%, to $750,532 for the six months of 2025, compared to $492,624 for the six months of 2024 due to sales of FemaSeed and FemVue.
|
| • |
Research and development expenses increased by $636,295, or 17.0%, to $4,382,901 for the six months of 2025 compared to $3,746,606 for the six months of 2024 primarily due to
increased compensation and regulatory costs, partially offset by reduced material and development costs and clinical costs.
|
| • |
Net loss was $10,482,761, or ($0.39) per basic and diluted share attributable to common stockholders, for the six-month period ended June 30, 2025, compared to a net loss of $8,284,084, or ($0.38)
per basic and diluted share attributable to common stockholders, for the same period ended June 30, 2024.
|
For more information, please refer to the Company’s Form 10-Q filed August 8, 2025, which can be accessed on the SEC
website.
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
|
Assets
|
June 30,
2025
|
December 31,
2024
|
||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
3,218,067
|
3,451,761
|
|||||
|
Accounts receivable, net
|
254,584
|
488,373
|
||||||
|
Inventory
|
5,232,738
|
3,046,323
|
||||||
|
Prepaid and other current assets
|
1,045,591
|
1,035,993
|
||||||
|
Total current assets
|
9,750,980
|
8,022,450
|
||||||
|
Property and equipment, at cost:
|
||||||||
|
Leasehold improvements
|
1,238,886
|
1,238,886
|
||||||
|
Office equipment
|
68,530
|
60,921
|
||||||
|
Furniture and fixtures
|
417,876
|
417,876
|
||||||
|
Machinery and equipment
|
3,211,109
|
2,856,740
|
||||||
|
Construction in progress
|
548,426
|
762,445
|
||||||
|
|
5,484,827
|
5,336,868
|
||||||
|
Less accumulated depreciation
|
(3,884,964
|
)
|
(3,740,769
|
)
|
||||
|
Net property and equipment
|
1,599,863
|
1,596,099
|
||||||
|
Long-term assets:
|
||||||||
|
Lease right-of-use assets, net
|
1,544,724
|
1,805,543
|
||||||
|
Intangible assets, net of accumulated amortization
|
55,638
|
65,918
|
||||||
|
Other long-term assets
|
829,204
|
954,992
|
||||||
|
Total long-term assets
|
2,429,566
|
2,826,453
|
||||||
|
Total assets
|
$
|
13,780,409
|
12,445,002
|
|||||
(continued)
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
|
Liabilities and Stockholders’ Equity
|
June 30,
2025
|
December 31,
2024
|
||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
3,263,584
|
1,419,044
|
|||||
|
Accrued expenses
|
1,052,752
|
1,151,049
|
||||||
|
Convertible notes payable, net (including related parties)
|
6,080,813
|
5,406,228
|
||||||
|
Clinical holdback – current portion
|
63,990
|
88,581
|
||||||
|
Lease liabilities – current portion
|
502,468
|
517,967
|
||||||
|
Total current liabilities
|
10,963,607
|
8,582,869
|
||||||
|
Long-term liabilities:
|
||||||||
|
Clinical holdback – long-term portion
|
40,348
|
39,611
|
||||||
|
Lease liabilities – long-term portion
|
1,269,019
|
1,518,100
|
||||||
|
Total long-term liabilities
|
1,309,367
|
1,557,711
|
||||||
|
Total liabilities
|
12,272,974
|
10,140,580
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity:
|
||||||||
|
Common stock, $.001 par, 200,000,000 authorized, 32,692,630 shares issued and 32,575,407 outstanding as of June 30, 2025; and 23,473,149 shares issued and 23,355,926 outstanding as of
December 31, 2024
|
32,693
|
23,473
|
||||||
|
Treasury stock, 117,223 common shares
|
(60,000
|
)
|
(60,000
|
)
|
||||
|
Warrants
|
1,821,744
|
1,860,008
|
||||||
|
Additional paid-in-capital
|
137,394,016
|
127,679,198
|
||||||
|
Accumulated deficit
|
(137,681,018
|
)
|
(127,198,257
|
)
|
||||
|
Total stockholders’ equity
|
1,507,435
|
2,304,422
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
13,780,409
|
12,445,002
|
|||||
FEMASYS INC.
Condensed Statements of Comprehensive Loss
(unaudited)
|
Three Months Ended June 30,
|
Six Months Ended June 30,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Sales
|
$
|
409,268
|
221,484
|
750,532
|
492,624
|
|||||||||||
|
Cost of sales (excluding depreciation expense)
|
158,171
|
73,125
|
275,437
|
161,657
|
||||||||||||
|
|
||||||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Research and development
|
1,414,429
|
1,975,875
|
4,382,901
|
3,746,606
|
||||||||||||
|
Sales and marketing
|
984,977
|
975,190
|
1,893,544
|
1,275,677
|
||||||||||||
|
General and administrative
|
1,616,972
|
1,611,817
|
3,339,685
|
3,114,621
|
||||||||||||
|
Depreciation and amortization
|
86,285
|
67,628
|
171,138
|
138,856
|
||||||||||||
|
Total operating expenses
|
4,102,663
|
4,630,510
|
9,787,268
|
8,275,760
|
||||||||||||
|
Loss from operations
|
(3,851,566
|
)
|
(4,482,151
|
)
|
(9,312,173
|
)
|
(7,944,793
|
)
|
||||||||
|
Other (expense) income:
|
||||||||||||||||
|
Interest income
|
17,144
|
184,138
|
36,173
|
408,822
|
||||||||||||
|
Interest expense
|
(491,500
|
)
|
(388,311
|
)
|
(950,949
|
)
|
(749,863
|
)
|
||||||||
|
Other expense
|
(260,000
|
)
|
—
|
(260,000
|
)
|
—
|
||||||||||
|
Total other expense, net
|
(734,356
|
)
|
(204,173
|
)
|
(1,174,776
|
)
|
(341,041
|
)
|
||||||||
|
Loss before income taxes
|
(4,585,922
|
)
|
(4,686,324
|
)
|
(10,486,949
|
)
|
(8,285,834
|
)
|
||||||||
|
Income tax benefit
|
—
|
(1,750
|
)
|
(4,188
|
)
|
(1,750
|
)
|
|||||||||
|
Net loss
|
$
|
(4,585,922
|
)
|
(4,684,574
|
)
|
(10,482,761
|
)
|
(8,284,084
|
)
|
|||||||
|
|
||||||||||||||||
|
Net loss attributable to common stockholders, basic and diluted
|
$
|
(4,585,922
|
)
|
(4,684,574
|
)
|
(10,482,761
|
)
|
(8,284,084
|
)
|
|||||||
|
Net loss per share attributable to common stockholders, basic and diluted
|
$
|
(0.16
|
)
|
(0.21
|
)
|
(0.39
|
)
|
(0.38
|
)
|
|||||||
|
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
|
28,880,704
|
22,215,516
|
27,025,277
|
21,995,436
|
||||||||||||
About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide
through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key
international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published
clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1
FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory
approval in Europe in June of 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®,
diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For
U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.
Learn more at www.femasys.com, or follow us on X,
Facebook and LinkedIn.
References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal
Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi:
10.33140/JGRM.08.02.08.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S.
C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1),
01-12. doi: 10.33140/JGRM.09.01.05.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be
identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could
cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include,
among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to
demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our
ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our
implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements
contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
Media: